Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure

ter Maaten, J. M. et al. (2016) Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circulation: Heart Failure, 9(8), e003109. (doi:10.1161/CIRCHEARTFAILURE.116.003109) (PMID:27507112)

[img]
Preview
Text
129508.pdf - Accepted Version

463kB

Abstract

Background—Chloride plays a role in renal salt sensing, neurohormonal activation, and regulation of diuretic targets, and hypochloremia predicts mortality in acute heart failure (AHF). AHF therapies, such as diuretics, alter chloride homeostasis. We studied the association between (changes in) chloride levels and diuretic responsiveness, decongestion, and mortality in patients with AHF. Methods and Results—Patients hospitalized for AHF in the PROTECT trial (n=2033) with serum chloride levels within 24 hours of admission and 14 days later were studied (n=1960). Hypochloremia was defined as serum chloride <96 mEq/L. Mean baseline chloride was 100.8±5.0 mEq/L. Low baseline chloride was associated with high bicarbonate, poor diuretic response, less hemoconcentration, and worsening heart failure (all P<0.01). Newly developed hypochloremia at day 14 was common and associated with a decline in renal function and an increase in blood urea nitrogen (P<0.01). In multivariable analyses, chloride measured at day 14, but not baseline chloride, was strongly and independently associated with mortality through 180 days (hazard ratio per unit decrease: 1.07 [1.03–1.10]; P<0.001). In comparison, sodium was not significantly associated with mortality after multivariable adjustment at any time point. Hypochloremia at baseline that resolved was not associated with mortality (P=0.55), but new or persistent hypochloremia at day 14 was associated with increased mortality (hazard ratio: 3.11 [2.17–4.46]; P<0.001). Conclusions—Low serum chloride at AHF hospital admission was strongly associated with impaired decongestion. New or persistent hypochloremia 14 days later was independently associated with reduced survival, whereas hypochloremia that resolved by day 14 was not. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00354458.

Item Type:Articles
Additional Information:The PROTECT trial was supported by NovoCardia, a subsidiary of Merck.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cleland, Professor John and Damman, Dr Kevin
Authors: ter Maaten, J. M., Damman, K., Hanberg, J. S., Givertz, M. M., Metra, M., O’Connor, C. M., Teerlink, J. R., Ponikowski, P., Cotter, G., Davison, B., Cleland, J. G.F., Bloomfield, D. M., Hillege, H. L., van Veldhuisen, D. J., Voors, A. A., and Testani, J. M.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Circulation: Heart Failure
Publisher:American Heart Association
ISSN:1941-3289
Copyright Holders:Copyright © 2016 American Heart Association, Inc.
First Published:First published in Circulation: Heart Failure 9(8): e003109
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record